Levodopa-induced ocular dyskinesias in Parkinson's disease

Movement Disorders

Volumn 17, Issue 1, 2002, Pages 186-187

  Linazasoro, Gurutz ^a   Van Blercom, Nadege ^a   Lasa, Asier ^a  

^a HOSPITAL QUIRÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE; BROMOCRIPTINE; BUDIPINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; SELEGILINE;

ADULT; ARTICLE; CASE REPORT; CAUDATE NUCLEUS; DENERVATION; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DYSKINESIA; EYE DISEASE; GAZE; HUMAN; HYPOTHESIS; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; REST; RIGIDITY; TREATMENT FAILURE;

ANTIPARKINSON AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; LEVODOPA; MALE; MIDDLE AGED; OCULAR MOTILITY DISORDERS; PARKINSON DISEASE;

EID: 0036460954     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10017     Document Type: Article

References (23)

1. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000(Suppl 1):S2-S11.
2. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124.
3. Shimizu N, Cohen B, Bala SP, Mendoza M, Yahr MD. Ocular dyskinesias in patients with Parkinson's disease treated with levodopa. Ann Neurol 1977;1:167-171.
4. LeWitt PA. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease. Mov Disord 1998;13:731-734.
5. Vidailhet M, Rivaud S, Gouider-Khouja N, Pillon B, Bonnet AM, Gaymard B, Agid Y, Pierrot-Deseilligny C. Eye movements in parkinsonian syndromes. Ann Neurol 1994;35:420-426.
6. Crawford TJ, Henderson L, Kennard C. Abnormalities of non-visually guided eye movements in Parkinson's disease. Brain 1989;112:1573-1586.
7. Bolger C, Bojanic S, Sheahan NF, Coakley D, Malone JF. Ocular microtremor in patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychistry 1999;66:528-531.
8. Rascol O, Clanet M, Montastruc JL, Simonetta M, Soulier-Esteve MJ, Doyon B, Rascol A. Abnormal ocular movements in Parkinson's disease. Brain 1989;112:1193-1214.
9. Sacks OW, Kohl M. L-dopa and oculogyric crises. Lancet 1970; 2:215-216.
10. Frankel M, Cummings JL. Neuro-ophtalmic abnormalities in Tourette's syndrome: functional and anatomic implications. Neurology 1984;34:359-361.
11. Shale H, Fahn S, Mayeux R. Tics in a patient with Parkinson's disease. Mov Disord 1986;1:79-83.
12. Kumar R, Lang AE. Coexistence of tics and parkinsonism: evidence for non-dopaminergic mechanisms in tic pathogenesis. Neurology 1997;49:1699-1701.
13. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Nigrostriatal denervation is required for induction of dyskinesias by L-dopa in squirrel monkeys. Clin Neuropharmacol 1990;13:448-458.
14. Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ. Relationship among nigrostriatal denervation, parkinsonism and dyskinesias in the MPTP primate model. Mov Disord 2000;15:459-466.
15. Horstink MW, Zijlmans JC, Pasman JW, Berger HJ, van't Hof MA. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990;53:224-226.
16. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996;23:189-193.
17. Kish SJ, Shannak HK, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
18. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity, Brain 1991;114:2283-2301.
19. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28: 547-555.
20. DeLong MR. Primate models of movement disorders of basal ganglia origin. TINS 1990;13:281-289.
21. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
22. Kunzle H. Bilateral projections from precentral motor cortex to the putamen and other parts of the basal ganglia. An autoradiographic study in Macaca fascicularis. Brain Res 1975;88:195-209.
23. Javoy Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson's disease?. Neurology 1980;30:1326-1330.